Mantle Cell Lymphoma

A real-world claims analysis linked zanubrutinib to improved time to next treatment and overall survival vs acalabrutinib in relapsed/refractory MCL.

Zanubrutinib plus R-BAP produced responses in both younger and older patients with previously untreated mantle cell lymphoma.

Frontline zanubrutinib plus rituximab demonstrated significant efficacy compared with SOC chemoimmunotherapy in patients with mantle cell lymphoma.

Sonrotoclax plus zanubrutinib yielded deep, durable responses at the recommended phase 2 dose in relapsed/refractory MCL.

LB2501, an off-the-shelf in vivo dual-target CAR T-cell therapy, produced a 100% ORR at dose level 2 across DLBCL, MCL, and follicular lymphoma.

Real-world data show liso-cel drives high response rates and durable benefit in relapsed/refractory MCL, including high-risk patients.

Rocbrutinib delivered durable responses and encouraging survival with manageable safety in BTK inhibitor–pretreated relapsed/refractory MCL.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in May 2026.

The top 5 OncLive TV videos of the week cover insights in breast cancer, ovarian cancer, prostate cancer, acute myeloid leukemia, and mantle cell lymphoma.

The top 5 OncLive TV videos of the week cover insights in breast cancer, ovarian cancer, prostate cancer, acute myeloid leukemia, and mantle cell lymphoma.

The FDA approved T-DXd in early HER2+ breast cancer, adjuvant atezolizumab in MRD+ MIBC, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The FDA granted accelerated approval to sonrotoclax for relapsed/refractory mantle cell lymphoma after at least 2 lines of systemic therapy.

Rituximab following first-line bendamustine demonstrated significant OS and EFS real-world benefits in mantle cell lymphoma.

Retrospective data showed zanubrutinib was associated with improved real-world overall survival vs ibrutinib in second- or third-line mantle cell lymphoma.

Luhua (Michael) Wang, MD, discusses the FDA approval of brexu-cel in mantle cell lymphoma and what to know about CAR T-cell therapy in clinical practice.

Lore Gruenbaum, PhD, discusses the direction mantle cell lymphoma is headed in addition to other critical areas of unmet needs.

Here is your cheat sheet to all oncology therapeutic options that were cleared or rejected by the FDA in April 2026.

The top 5 OncLive TV videos of the week cover insights in mantle cell lymphoma, endometrial cancer, salivary gland cancer, myeloproliferative neoplasms, and renal cell carcinoma.

Significantly improved response rates were shown for liso-cel vs real-world data for SOC in later-line relapsed or refractory mantle cell lymphoma.

The top 5 OncLive TV videos of the week cover insights in mantle cell lymphoma, chronic lymphocytic leukemia, salivary gland cancer, cholangiocarcinoma, and prostate cancer.

Lore Gruenbaum, PhD, discusses hot topics in mantle cell lymphoma, such as recently approved CAR T-cell therapies and where she sees the field moving next.

The final analysis of the phase 1/2 BRUIN trial showed consistent stability or improvements in PROs with pirtobrutinib in CLL/SLL and MCL.

The FDA grants full approval to brexu-cel in mantle cell lymphoma, grants priority review to a lirafugratinib NDA in FGFR2+ pretreated cholangiocarcinoma, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.